-
2023-505812-39-00
5
2020-08-28
HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI
-
2023-509242-35-00
5
2020-07-23
HR+/HER2- early breast cancer
-
2024-511940-20-00
5
2020-02-05
Parkinson's disease
-
2023-510268-11-00
4
2019-06-11
Cervical cancer
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2024-511648-16-00
5
2019-01-04
Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresecta
-
2024-510967-41-00
5
2018-09-21
Metastatic colorectal cancer
-
2023-505341-23-00
5
2018-07-27
Non-muscle invasive bladder cancer
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2025-521810-24-00
6
2025-09-22
Breast cancer
-
2024-512848-30-00
4
2024-11-12
HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
-
2023-507173-18-00
4
2024-04-09
HIV Infections
-
2023-507358-34-00
4
2024-02-13
For the treatment of patients with chronic non-specific low back pain
-
2023-505458-16-00
5
2022-09-13
Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
-
2024-513992-42-00
10
2022-09-13
venous thromboembolism (VTE) in patients with gastrointestinal/genitou
-
2023-509569-19-00
10
2022-08-10
venous thromboembolism (VTE)
-
2023-509095-42-00
4
2022-07-14
Colorectal cancer
-
2024-519691-10-00
6
2022-05-27
Septic Shock
-
2024-514570-43-00
5
2022-01-24
Renal cell carcinoma
-
2024-518875-73-00
5
2021-12-10
Huntington Disease
-
2024-515167-56-00
11
2021-06-22
HIV
-
2024-514803-33-00
4
2021-06-16
Non-small cell lung cancer (NSCLC)
-
2024-512123-37-00
5
2021-05-27
Parkinson's disease
-
2023-507317-10-00
5
2021-05-10
Locally advanced, unresectable, or metastatic non small cell lung canc